keyword
MENU ▼
Read by QxMD icon Read
search

Acthar

keyword
https://www.readbyqxmd.com/read/27642533/repository-corticotropin-injection-for-treatment-of-idiopathic-inflammatory-myopathies
#1
Aarat Patel, Georgia Seely, Rohit Aggarwal
Idiopathic inflammatory myopathies are a group of systemic autoimmune diseases that involve inflammation of skeletal muscle. The two most common forms are dermatomyositis and polymyositis, the former of which entails a skin component. There are few approved therapeutics available for treatment of this group of diseases and the first-line therapy is usually corticosteroid treatment. Considering that a large proportion of patients do not respond to or cannot tolerate corticosteroids, additional treatments are required...
2016: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/27478599/pneumococcal-hemolytic-uremic-syndrome-and-steroid-resistant-nephrotic-syndrome
#2
Andrew P Groves, Patrick Reich, Binayak Sigdel, T Keefe Davis
Pneumococcal-associated hemolytic uremic syndrome (pHUS) is a rare but severe complication of invasive Streptococcus pneumoniae infection. We report the case of a 12-year-old female with steroid-resistant nephrotic syndrome treated with adrenocorticotrophic hormone (H.P. Acthar(®) Gel), who developed pneumococcal pneumonia and subsequent pHUS. While nephrotic syndrome is a well-known risk factor for invasive pneumococcal disease, this is the first reported case of pHUS in an adolescent patient with nephrotic syndrome, and reveals novel challenges in the diagnosis, treatment and potential prevention of this complication...
August 2016: Clinical Kidney Journal
https://www.readbyqxmd.com/read/27433309/h-p-acthar-gel-repository-corticotropin-injection-treatment-of-patients-with-multiple-sclerosis-and-diabetes
#3
Christen Kutz
BACKGROUND: Treatment of multiple sclerosis (MS) relapses can be complex in patients with concomitant diabetes. Corticosteroids and adrenocorticotropic hormones are known to cause alterations in glucose tolerance. Many patients have poor tolerability to therapy, necessitating alternative treatment options. Adrenocorticotropic hormone (H.P. Acthar Gel, repository corticotropin injection, Mallinckrodt ARD Inc., Hazelwood, MO, USA) is currently indicated for the treatment of MS relapses...
July 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/27418857/adrenocorticotropic-hormone-analog-use-for-podocytopathies
#4
Edward J Filippone, Shirley J Dopson, Denise M Rivers, Rebeca D Monk, Suneel M Udani, Golriz Jafari, Solomon C Huang, Arafat Melhem, Bassim Assioun, Paul G Schmitz
BACKGROUND: Adrenocorticotropic hormone is being increasingly studied for treatment of various glomerulopathies, most notably membranous nephropathy. Less data are available regarding its use in idiopathic nephrotic syndrome (INS) secondary to minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). We report here our experience with H.P. Acthar(®) Gel (repository corticotropin injection) as first-line or subsequent therapy in patients with INS. METHODS: Data were taken from three patients with MCD and ten patients with FSGS from around the US, who were treated with Acthar Gel as initial or subsequent therapy...
2016: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/27324137/healthcare-costs-and-resource-utilization-in-patients-with-infantile-spasms-treated-with-h-p-acthar-gel-%C3%A2
#5
Laura S Gold, Patricia B Schepman, Wei-Jhih Wang, Michael Philbin, John Niewoehner, Kavitha Damal, Ryan N Hansen
INTRODUCTION: The purpose of this study was to describe healthcare resource utilization and costs resulting from early (within 30 days of diagnosis) versus late (>30 days after diagnosis) treatment with prescriptions for H.P. Acthar(®) Gel (repository corticotropin injection; Acthar; Mallinckrodt) to manage infantile spasms (IS). METHODS: We included all patients in the Truven Health MarketScan(®) Commercial Claims and Encounters Database and the Truven Health MarketScan Multi-State Medicaid Database who were diagnosed with IS from 2007 to 2012...
August 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27312977/healthcare-costs-and-resource-utilization-in-patients-with-multiple-sclerosis-relapses-treated-with-h-p-acthar-gel-%C3%A2
#6
Laura S Gold, Kangho Suh, Patricia B Schepman, Kavitha Damal, Ryan N Hansen
INTRODUCTION: Multiple sclerosis (MS) is an autoimmune disorder with large annual costs. This study evaluated utilization and costs for the management of MS relapses with H.P. Acthar(®) Gel (repository corticotropin injection; Acthar; Mallinckrodt) compared to receipt of plasmapheresis (PMP) or intravenous immunoglobulin (IVIG) among patients with MS who experienced multiple relapses. METHODS: We identified patients with MS diagnoses who had relapses treated with intravenous methylprednisolone (IVMP), the first-line treatment for MS relapse...
August 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27222775/sarcoidosis-patient-with-lupus-pernio-and-infliximab-induced-myositis-response-to-acthar-gel
#7
Ying Zhou, Elyse E Lower, Huiping Li, Robert P Baughman
Infliximab is an effective treatment for sarcoidosis patients with persistent disease despite glucocorticoids and immunosuppressive therapy. Patients receiving infliximab can experience side effects, inducing an autoimmune reaction. Treatment is unclear for sarcoidosis patients who develop autoimmune reactions to infliximab. We report a case of a patient with advanced sarcoidosis who developed a myositis type reaction to infliximab characterized by diffuse muscle achiness and weakness and marked elevations in serum creatinine phosphokinase (CPK) and aldolase...
2016: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/27134674/clinical-experience-with-repository-corticotropin-injection-in-patients-with-multiple-sclerosis-experiencing-mood-changes-with-intravenous-methylprednisolone-a-case-series
#8
REVIEW
Stacey Murray, Andrew Woo
The elevated prevalence of neuropsychiatric symptoms and disorders among patients with multiple sclerosis (MS) is well recognized, as are potential neuropsychiatric side effects of treatment with corticosteroids. Both methylprednisolone (MP) and repository corticotropin injection (HP Acthar(®) gel) have demonstrated efficacy in reducing short-term disability after exacerbations of MS. Although historical data are limited, repository corticotropin injection has not generally been associated with detrimental neuropsychiatric effects...
May 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27036111/acthar-gel-in-the-treatment-of-nephrotic-syndrome-a-multicenter-retrospective-case-series
#9
MULTICENTER STUDY
Arvind Madan, Snezana Mijovic-Das, Ana Stankovic, Geoffrey Teehan, Amber S Milward, Anupa Khastgir
BACKGROUND: Current first-line anti-proteinuric treatments for nephrotic syndrome (NS) do not produce an effective response in all patients and are not tolerated by some patients. Additional effective and tolerable treatment options in NS are strongly needed. This retrospective case series is the largest to date to examine Acthar gel (adrenocorticotropic hormone, ACTH) in patients with varied-etiology NS. METHODS: This multicenter retrospective case series included adult patients with NS (N = 44) treated with Acthar gel at 6 clinical practices...
March 31, 2016: BMC Nephrology
https://www.readbyqxmd.com/read/26836915/finding-common-ground-professionalism-and-acthar-prescribing-practices
#10
EDITORIAL
Don Liss, Troyen A Brennan, Scott Manaker
No abstract text is available yet for this article.
March 2016: Chest
https://www.readbyqxmd.com/read/26626451/a-retrospective-pilot-study-examining-the-use-of-acthar-gel-in-sarcoidosis-patients
#11
Robert P Baughman, Joseph B Barney, Lanier O'Hare, Elyse E Lower
INTRODUCTION: Acthar was reported as effective for the treatment of pulmonary sarcoidosis in the 1950s. Use of drug waned due to cost and toxicity compared to prednisone. Recent interest has reemerged as an alternative to high dose oral glucocorticoids. METHODS: Chart review was performed on all advanced sarcoidosis patients seen at two centers who received at least one dose of Acthar gel therapy with at least six months of posttreatment follow up. In all cases prior sarcoidosis therapy and indications for use along with clinical outcome were noted...
January 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/26507974/direct-effects-of-hp-acthar-gel-on-human-b-lymphocyte-activation-in-vitro
#12
Nancy J Olsen, Dima A Decker, Paul Higgins, Patrice M Becker, Carl A McAloose, Ann L Benko, William J Kovacs
INTRODUCTION: Both clinical experience and experimental evidence have suggested that Adrenocorticotropic hormone (ACTH) might directly exert immunomodulatory effects not dependent on adrenal steroidogenesis. METHODS: The direct effects of H.P. Acthar Gel (Acthar), a repository preparation containing a porcine ACTH analogue, on human B lymphocyte function were studied in vitro using peripheral blood B cells isolated using anti-CD19 coated magnetic beads and activated by interleukin 4 (IL-4) and CD40 ligand (CD40L)...
2015: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/25955410/acth-acthar-gel-reduces-toxic-sod1-protein-linked-to-amyotrophic-lateral-sclerosis-in-transgenic-mice-a-novel-observation
#13
Hasan Arrat, Thomas J Lukas, Teepu Siddique
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a complex etiology and pathology that makes the development of new therapies difficult. ACTH has neurotrophic and myotrophic effects, but has not been tested in an ALS mouse model. The G93A-SOD1 mouse model of ALS was used to test the ability of this drug to delay ALS-like symptoms. We showed that within a specific dose range, ACTH significantly postponed the disease onset and paralysis in the mouse model. To our surprise and of greater significance is that ACTH significantly reduced the levels of soluble SOD1 in the spinal cord and CNS tissues of G93A-SOD1 treated mice as well as cultured fibroblasts...
2015: PloS One
https://www.readbyqxmd.com/read/25853133/a-case-report-of-adrenocorticotropic-hormone-to-treat-recurrent-focal-segmental-glomerular-sclerosis-post-transplantation-and-biomarker-monitoring
#14
Siddiq Anwar, Derek S Larson, Nima Naimi, Muhammad Ashraf, Nancy Culiberk, Helen Liapis, Changli Wei, Jochen Reiser, Daniel C Brennan
BACKGROUND: Recurrent focal segmental glomerular sclerosis (rFSGS) in renal transplant recipients (RTR) is difficult to predict and treat. Early rFSGS is likely from circulating factors and preformed antibodies. METHODS: We present the case of a 23-year-old white man who presented with rFSGS and acute renal failure, requiring dialysis 9-months after a 1-haplotype matched living-related transplant. We retrospectively analyzed serum samples from various clinical stages for rFSGS biomarkers: serum glomerular albumin permeability (Palb), soluble urokinase-type plasminogen activator receptor (suPAR) serum level with suPAR-β3 integrin signaling on human podocytes, and angiotensin II type I receptor-antibody (AT1R-Ab) titer...
2015: Frontiers in Medicine
https://www.readbyqxmd.com/read/25848316/repository-corticotropin-injection-in-a-patient-presenting-with-focal-segmental-glomerulosclerosis-rheumatoid-arthritis-and-optic-neuritis-a-case-report
#15
Arvind Madan
BACKGROUND: Focal segmental glomerulosclerosis (FSGS) causes scarring or sclerosis of glomeruli that act as tiny filters in the kidneys, damage to which results in diminished ability to properly filter blood, resulting in the urinary loss of plasma proteins and subsequent proteinuria. CASE PRESENTATION: A 60-year-old, white female with a history of intermittent proteinuria was referred by her primary care physician for renal dysfunction. Biopsy confirmed FSGS and she was treated with an angiotensin-converting enzyme inhibitor...
2015: International Journal of General Medicine
https://www.readbyqxmd.com/read/25410153/acthar-gel-treatment-suppresses-acute-exacerbations-in-a-murine-model-of-relapsing-remitting-multiple-sclerosis
#16
Matthew F Cusick, Jane E Libbey, Luke Oh, Shaun Jordan, Robert S Fujinami
Acthar gel is indicated for the treatment of acute exacerbations of multiple sclerosis (MS) in adults. Its effects on immune cells during a relapse are unknown. This study investigated the effects of Acthar in an animal model of relapsing-remitting MS, using SJL/J mice sensitized with myelin peptide. All animal studies were reviewed and approved by the University of Utah Institutional Animal Care and Use Committee and conducted in accordance with the guidelines prepared by the Committee on Care and Use of Laboratory Animals, Institute of Laboratory Animals Resources, National Research Council...
June 2015: Autoimmunity
https://www.readbyqxmd.com/read/24795067/treatment-of-moderately-to-severely-active-systemic-lupus-erythematosus-with-adrenocorticotropic-hormone-a-single-site-open-label-trial
#17
J J Fiechtner, T Montroy
BACKGROUND: Alternative therapeutic options are needed for patients with systemic lupus erythematosus (SLE) not adequately controlled with or intolerant to traditional treatments. This study evaluated the efficacy of Acthar® Gel (ACTH(1-39)) for reducing active SLE severity among patients receiving underlying conventional maintenance therapies. METHODS: Ten females (mean age = 49 yrs, disease duration = 7 yrs, Systemic Lupus Erythematosus Disease Activity Index-2000 [SLEDAI-2 K] = 10) currently on maintenance self-administered ACTH(1-39) gel 1 mL (80 U/mL) for 7-15 days and were assessed weekly for 28 days...
August 2014: Lupus
https://www.readbyqxmd.com/read/24759631/immunomodulatory-effects-of-h-p-acthar-gel-on-b-cell-development-in-the-nzb-w-f1-mouse-model-of-systemic-lupus-erythematosus
#18
D A Decker, C Grant, L Oh, P M Becker, D Young, S Jordan
H.P. Acthar Gel® (Acthar) is a highly purified repository gel preparation of adrenocorticotropic hormone (ACTH1-39), a melanocortin peptide that can bind and activate specific receptors expressed on a range of systemic lupus erythematosus (SLE)-relevant target cells and tissues. This study was performed to evaluate the effects of Acthar in a mouse model of SLE, using an F1 hybrid of the New Zealand Black and New Zealand White strains (NZB/W F1). Twenty-eight week old NZB/W F1 mice with established autoimmune disease were treated with Acthar, Placebo Gel (Placebo), or prednisolone and monitored for 19 weeks...
July 2014: Lupus
https://www.readbyqxmd.com/read/24714414/a-pilot-study-to-determine-the-dose-and-effectiveness-of-adrenocorticotrophic-hormone-h-p-acthar%C3%A2-gel-in-nephrotic-syndrome-due-to-idiopathic-membranous-nephropathy
#19
RANDOMIZED CONTROLLED TRIAL
Michelle A Hladunewich, Daniel Cattran, Laurence H Beck, Ayodele Odutayo, Sanjeev Sethi, Rivka Ayalon, Nelson Leung, Heather Reich, Fernando C Fervenza
BACKGROUND: H.P. Acthar(®) Gel is currently the only Food and Drug Administration therapy approved for the treatment of nephrotic syndrome. Active drug ingredients include structurally related melanocortin peptides that bind to cell surface G-protein-coupled receptors known as melanocortin receptors, which are expressed in glomerular podocytes. In animal models of membranous nephropathy, stimulation has been demonstrated to reduce podocyte injury and loss. We hypothesized that H.P. Acthar(®) Gel would improve symptoms of the nephrotic syndrome in patients with idiopathic membranous nephropathy...
August 2014: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/24174881/membranous-glomerulopathy-and-treatment-with-acthar%C3%A2-a-case-study
#20
Myra June Watson
Treatment options for refractory membranous nephropathy are limited. Herein we describe the case of a 46-year-old white male with membranous nephropathy who progressed during 3 years of treatment with antihypertensive agents (specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers), diuretics, simvastatin, prednisone, cyclosporine A, and mycophenolate mofetil. Prior to initiation of treatment with H.P. Acthar® Gel, his proteinuria level was 9,520 mg/dL (952.0 g/L) but it decreased to 2,948 mg/dL (294...
2013: International Journal of Nephrology and Renovascular Disease
keyword
keyword
92576
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"